Essity doubles down on feminine care with Brazil deal while its last acquisition is still being integrated

Essity Aktiebolag (publ) (Nasdaq Stockholm: ESSITY B) has agreed to acquire Kenvue Inc.’s feminine care business in Brazil for $284 million, or approximately SEK 2.7 billion, extending an acquisition-led push into a category that is already one of the strongest growth engines inside its Personal Care division. The asset purchase covers the Carefree, Sempre Livre and o.b. brands for sanitary pads, liners and tampons, together with related manufacturing equipment, and brings a business generating approximately BRL 800 million, or SEK 1.4 billion, of trailing 12-month sales through June 2026. The transaction gives Essity a much stronger position in Brazil, which the company identifies as the world’s fourth-largest feminine care market, while building on its existing presence in the country through TENA, Professional Hygiene and Medical Solutions. The strategic fit is relatively straightforward, but the more important investor question is whether Essity can justify a purchase price equivalent to roughly 1.9 times trailing sales while simultaneously absorbing its recently acquired North American feminine care operations.

The timing adds another layer of complexity. Essity expects the Brazilian acquisition to close only during the second quarter of 2027, subject to Brazilian regulatory approval, customary conditions and completion of Kimberly-Clark Corporation’s separate acquisition of Kenvue. Kenvue said in its latest second-quarter update that its transaction with Kimberly-Clark is currently expected to close in the fourth quarter of 2026, meaning Essity’s Brazilian expansion is effectively sitting behind another large corporate transaction before it can reach completion.

Why is Essity willing to pay about 1.9 times sales for Kenvue’s feminine care business in Brazil?

The valuation is the first number that deserves attention. Essity is paying approximately SEK 2.7 billion for a business with trailing sales of about SEK 1.4 billion, implying a purchase price of roughly 1.9 times annual revenue. Kenvue’s Brazilian operations were described by Essity as having good profitability, but the company did not disclose EBITDA, operating profit or a transaction EBITDA multiple. That absence matters because it prevents a direct assessment of how much of the apparent sales premium is supported by higher underlying margins.

There is nevertheless a useful comparison inside Essity’s own recent deal history. Its acquisition of Edgewell Personal Care Company’s feminine care business in North America, completed in February 2026, was announced at a purchase price of $340 million against trailing sales of $261 million, equivalent to approximately 1.3 times sales. Essity disclosed an EBITDA multiple of about 12.1 times for that transaction before estimated run-rate synergies and approximately 8.3 times after those synergies. On a simple sales basis, the Brazilian acquisition is therefore being struck at a multiple roughly 48% higher than the North American deal, although differences in profitability, brand positioning, manufacturing assets, market structure and expected growth mean the comparison cannot be treated as an apples-to-apples valuation test.

What Essity appears to be buying is not simply BRL 800 million of existing revenue. Carefree, Sempre Livre and o.b. provide established consumer positions across several feminine care formats in a market that Essity considers structurally attractive, while the inclusion of manufacturing equipment may give the company more control over the operating platform than a pure brand-licensing transaction would provide. Essity already has local infrastructure through its TENA production facility in Jarinu, and that existing commercial footprint could eventually support distribution, procurement, marketing and administrative efficiencies across a broader Brazilian Personal Care portfolio. Essity has not quantified such synergies, however, so they should be treated as potential upside rather than embedded economics.

How does the Brazil acquisition fit Essity’s increasingly aggressive feminine care expansion strategy?

Feminine Care is becoming progressively more important to Essity’s growth profile. In the second quarter of 2026, Personal Care generated SEK 8.815 billion of net sales and organic growth of 3.8%, while Feminine Care itself delivered organic growth of 5.9%. Feminine Care represented 47% of Personal Care sales during the quarter, making it the largest category within that business area ahead of Incontinence Products Retail and Baby Care.

That category mix helps explain why another acquisition has arrived only months after Essity completed the North American transaction. The company is allocating capital toward businesses where its existing organic performance is already stronger rather than attempting to buy growth into a structurally weak category. Brazil also extends a Latin American feminine care portfolio that includes brands such as Nosotras and Saba, meaning the acquired brands can sit inside an established regional category platform rather than requiring Essity to build a feminine care organization from scratch.

The broader portfolio strategy is also becoming more visible. Essity has been emphasizing Health & Medical and Personal Care while simultaneously reviewing its Consumer Tissue operations. Management said after the second quarter that portfolio optimization and the feminine care acquisition strategy were intended to strengthen value creation, while cost reductions would release resources for investment in brands, innovation and growth. The Brazilian deal therefore looks less like an isolated bolt-on and more like another step in shifting capital toward categories where management believes returns and long-term growth prospects are more attractive.

Could Essity’s North American feminine care integration reveal the biggest risk in the Brazil deal?

The recent North American acquisition provides an unusually timely warning against assuming that additional sales translate immediately into better margins. Essity reported that the North American feminine care acquisition contributed 7.7 percentage points to Personal Care’s reported sales movement in the second quarter, but it also had a negative effect on the division’s margin because Essity had limited flexibility to manage higher costs during the transition period.

Personal Care’s EBITA excluding items affecting comparability increased only slightly to SEK 1.131 billion from SEK 1.120 billion despite the division’s substantial reported sales increase. Its adjusted EBITA margin fell to 12.8% from 14.4%, with Essity attributing pressure to lower selling prices, higher cost of goods sold, increased marketing expenditure and the North American acquisition. The business is growing, but the margin data demonstrate why investors should distinguish between gaining category scale and converting that scale into operating leverage.

The Brazilian acquisition does not close until 2027, giving Essity time to progress the North American integration before another sizable feminine care platform enters the group. That timing could ultimately be advantageous. It also creates a measurable benchmark: if margins and profitability in Personal Care improve as the North American transition matures, management will enter the Brazilian integration with stronger evidence that its acquisition model can create value after the initial transition costs.

The opposite would be more concerning. If Personal Care margins remain under pressure even after the North American business is substantially integrated, investors may become less willing to give Essity the benefit of the doubt on another acquisition made at a comparatively higher sales multiple. The investment case therefore depends not merely on how quickly Brazilian sales grow after closing, but on whether Essity can preserve brand investment while extracting enough operational efficiency to protect category returns.

Does Essity have enough balance-sheet capacity to fund another SEK 2.7 billion acquisition?

Essity enters the transaction with a comparatively manageable leverage position. Net debt was SEK 28.462 billion at June 30, 2026, compared with SEK 34.177 billion a year earlier, while net debt to EBITDA excluding items affecting comparability stood at 1.11 times. First-half operating cash flow reached SEK 7.144 billion, up 35% from SEK 5.305 billion in the corresponding period of 2025.

The SEK 2.7 billion purchase price is equivalent to roughly 9.5% of Essity’s June net debt and about 38% of the operating cash flow generated during the first half of 2026. Those comparisons do not indicate how Essity will ultimately finance the acquisition, which has not yet closed, but they show that the deal is meaningful without appearing transformational for the group’s balance sheet.

Capital allocation is worth monitoring because Essity is not standing still elsewhere. The company began a new SEK 3 billion Class B share buyback programme in May, and management has described recurring buybacks funded from operating cash flow after the ordinary dividend as part of its capital allocation approach. The combination of acquisitions, shareholder distributions and continued investment in growth therefore puts a premium on sustained cash generation, particularly if inflationary pressure continues across transport, energy and other inputs.

For investors, this means the Brazil transaction is unlikely to be judged primarily as a leverage story unless Essity announces additional major deals before closing. The more relevant capital-allocation question is whether deploying SEK 2.7 billion into feminine care can eventually produce returns superior to alternative uses of that cash, including buybacks, organic expansion or investment elsewhere in Personal Care.

What does Essity’s share price say before investors get their first chance to react to the Brazil acquisition?

Essity’s Class B shares closed at SEK 271.20 on August 19, up 0.11% for the session, with a market capitalization of approximately SEK 184.95 billion. The important timing detail is that Essity released the acquisition announcement at 19:00 Central European Time, after Nasdaq Stockholm trading had finished, so the August 19 closing price does not represent a market reaction to the Brazil transaction. The first regular trading session after the announcement will therefore provide the cleaner initial sentiment signal.

The shares had already softened before the deal. The August 19 close of SEK 271.20 was about 1.5% below the August 12 close of SEK 275.30 and approximately 3.6% below the SEK 281.30 level recorded on July 20. Even after that retreat, Essity remained about 15% above its 52-week low of SEK 236.10 and roughly 7.5% below its 52-week high of SEK 293.10.

Institutional sentiment has also been mixed rather than uniformly bullish. A recent 15-analyst consensus compiled by Investing.com showed five buy ratings, six holds and four sells, with an average 12-month target of SEK 271.60, almost exactly where the shares closed before the Brazilian acquisition was announced. Goldman Sachs downgraded Essity to sell in late July with a SEK 255 target, while other recent broker moves have ranged from cautious ratings to more constructive views on improving volume trends. That dispersion suggests investors are still debating how much value to assign to Essity’s volume recovery, margin trajectory and portfolio repositioning.

The Brazilian acquisition could strengthen the growth argument because it expands one of Essity’s faster-growing categories, but it does not remove the existing margin debate. A positive initial share-price response would indicate that investors are willing to prioritize strategic category expansion and Brazil’s growth opportunity. A muted or negative response would more likely suggest concern about valuation, integration demands or the amount of capital being committed before the benefits of the North American acquisition are fully visible.

What needs to happen before Essity’s $284 million Brazil feminine care acquisition can create measurable value?

The first milestone is external rather than operational. Kimberly-Clark’s acquisition of Kenvue must progress to completion, with Kenvue currently expecting that transaction in the fourth quarter of 2026, after which Essity still requires Brazilian regulatory approval and satisfaction of other closing conditions before its own transaction can complete. Essity is targeting the second quarter of 2027.

After closing, the most important evidence will come from Personal Care margins, organic feminine care growth and management disclosure around synergies or integration costs. Essity has already demonstrated that an acquired feminine care business can add substantial reported revenue while temporarily weighing on margins. The Brazilian acquisition will need to do more than expand market share: it must eventually convert brand strength, manufacturing assets and an existing Brazilian infrastructure into returns capable of supporting the roughly 1.9 times sales purchase price.

The strategic direction is increasingly clear. Essity wants greater exposure to categories such as Feminine Care where demand, brand differentiation and volume growth appear stronger, and Brazil gives it access to a large consumer market where it already operates other hygiene and health businesses. What remains unresolved is whether the economics can catch up with the strategic logic. The strongest evidence would be a recovery in Personal Care profitability during the North American integration, followed by sustained organic growth and margin discipline once Carefree, Sempre Livre and o.b. enter Essity’s Brazilian portfolio.

Key takeaways from Essity’s $284 million Kenvue feminine care acquisition in Brazil

• Essity agreed to acquire Kenvue’s feminine care business in Brazil for $284 million, approximately SEK 2.7 billion, on a cash and debt-free basis.
• The transaction includes Carefree, Sempre Livre and o.b., along with related Brazilian manufacturing equipment.
• The acquired operation generated approximately BRL 800 million, or SEK 1.4 billion, of net sales during the 12 months ended June 2026.
• The purchase price equates to roughly 1.9 times trailing sales, compared with about 1.3 times sales for Essity’s recent North American feminine care acquisition.
• Brazil is the world’s fourth-largest feminine care market according to Essity, while the company already operates locally through TENA and other hygiene and medical businesses.
• Feminine Care delivered 5.9% organic growth in Essity’s second quarter and represented 47% of Personal Care sales, reinforcing the strategic rationale for further category investment.
• Personal Care’s adjusted EBITA margin fell to 12.8% from 14.4% in the second quarter, with the North American acquisition among the factors weighing on profitability during integration.
• Essity’s net debt to EBITDA excluding items affecting comparability stood at a manageable 1.11 times at June 30, providing balance-sheet flexibility for the transaction.
• The deal is expected to close in the second quarter of 2027 and remains dependent on Brazilian regulatory approval and completion of Kimberly-Clark’s acquisition of Kenvue.
• The next strategic proof point is whether Essity can restore Personal Care margins while maintaining feminine care growth, providing evidence that acquisition-driven scale is translating into stronger returns.